Kurse werden geladen...
Prognose
| Kaufen | 4 |
| Halten | 0 |
| Verkaufen | 0 |
Scoring-Modelle
| Dividenden-Strategie | 0 / 15 |
| HGI-Strategie | 3 / 18 |
| Levermann-Strategie | -4 / 13 |
News
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25
SPRING Trial Data Presented at BSG Live'25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is Well-Tolerated and Associated with Substantial Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of PSC Disease Progression TEL AVIV, Israel and GLASGOW, United Kingdom, June 30, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that data from the company's Phase 2 SPRING trial of nebokitug (CM-101) in patients with primary sclerosing cholangitis (PSC) was presented in an oral session1 at BSG Live'25, the annual scientific meeting of the British Society for Gastroenterology, in Glasgow, UK.» Mehr auf globenewswire.com
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strategic Partners Continue— TEL AVIV, Israel, June 11, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported that it has obtained confirmation from the FDA on two significant development milestones as the company continues to finalize the nebokitug Phase 3 program.» Mehr auf globenewswire.com
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
—New Patent s Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up T o 2041 — —Further Ex pands Protections Provided by Nebokitug 's Composition of Matter and Methods and Use Patents Issued in the U.S., Europe, Japan and A dditional Key Territories— TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that its lead product nebokitug (formerly CM-101) has been awarded new patent protections in China and Russia.» Mehr auf globenewswire.com
Unternehmenszahlen
| (EUR) | März 2025 | |
|---|---|---|
| Umsatz | 0,00 | - |
| Bruttoeinkommen | 0,00 | - |
| Nettoeinkommen | −3,07 Mio | 15,24% |
| EBITDA | −3,22 Mio | 14,06% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 931,45k€ |
Anzahl Aktien | 943,14k |
52 Wochen-Hoch/Tief | 2,17€ - 0,74€ |
| Dividenden | Nein |
Beta | 0,62 |
KGV (PE Ratio) | −1,97 |
KGWV (PEG Ratio) | −0,13 |
KBV (PB Ratio) | 1,95 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Chemomab Therapeutics Ltd. ist ein in der klinischen Phase befindliches Biotech-Unternehmen, das Therapeutika zur Behandlung von Entzündungen und Fibrose erforscht und entwickelt. Der führende klinische Produktkandidat des Unternehmens ist CM-101, ein humanisierter monoklonaler Antikörper, der die grundlegende Funktion des löslichen Chemokins CCL24 für die Behandlung der primär sklerosierenden Cholangitis (PSC) und der systemischen Sklerose (SSc) hemmt. Das Unternehmen war früher als Anchiano Therapeutics Ltd. bekannt und änderte im März 2021 seinen Namen in Chemomab Therapeutics Ltd. Chemomab Therapeutics Ltd. wurde im Jahr 2011 gegründet und hat seinen Sitz in Tel Aviv, Israel.
| Name | Chemomab Therapeutics ADR Aktie |
| CEO | Adi Mor George |
| Sitz | Tel Aviv, Israel |
| Website | |
| Industrie | Chemikalien |
| Börsengang | |
| Mitarbeiter | 20 |
Ticker Symbole
| Börse | Symbol |
|---|---|
NASDAQ | CMMB |
Frankfurt | 2QV0.F |
Düsseldorf | 2QV0.DU |
München | 2QV0.MU |
Assets entdecken
Shareholder von Chemomab Therapeutics ADR Aktie investieren auch in folgende Assets
